Literature DB >> 29452038

Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary.

.   

Abstract

of recommendations from ASCO and the American Urological Association regarding the chemoprevention of prostate cancer and use of 5-α-reductase inhibitors.

Entities:  

Year:  2009        PMID： 29452038      PMCID： PMC2790690          DOI： 10.1200/JOP.0938503

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  4 in total

Review 1.  Five-alpha-reductase Inhibitors for prostate cancer prevention.

Authors:  T J Wilt; R MacDonald; K Hagerty; P Schellhammer; B S Kramer
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

2.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Authors:  Gerald Andriole; David Bostwick; Otis Brawley; Leonard Gomella; Michael Marberger; Donald Tindall; Sharon Breed; Matt Somerville; Roger Rittmaster
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

3.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 4.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Clin Oncol       Date:  2009-02-24       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.